Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | RPA1 | P27694 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678118 | 0.90 | PTGDR2 (0.32) | CXCR3KDM1ACYP2C19BRAFGPR35 | |
| SCHEMBL4678455 | 0.84 | CHEK2 (0.32) | CHEK2BRAFALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4679497 | 0.82 | CXCR3 (0.34) | CXCR3KDM1ACHEK2PYGLTBXA2R | |
| SCHEMBL4676467 | 0.81 | CXCR3 (0.36) | CXCR3TBXA2RALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4675056 | 0.80 | CXCR3 (0.33) | CXCR3KDM1ACHEK2PYGLTBXA2R | |
| SCHEMBL4673903 | 0.78 | CXCR3 (0.32) | CXCR3CYP2C19ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4677037 | 0.78 | CXCR3 (0.32) | CXCR3KDM1APYGLALDH1A1CYP3A4 | |
| SCHEMBL4676059 | 0.78 | AKR1C3 (0.38) | CHEK2BRAFALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4676054 | 0.78 | AKR1C3 (0.38) | CHEK2BRAFALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4675743 | 0.77 | AKR1B1 (0.41) | CXCR3KDM1ACHEK2PYGLTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1142872-B1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7098201-B2 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | FUJISHITA TOSHIO (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6645956-B1 | 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment | SHIONOGI & CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6620841-B1 | Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) | SHIONOGI & CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| EP-1142872-A1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | RCOR1, BCOR, CYP8B1 | CXCR3 1130/4885KDM1A 583/4885CHEK2 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.